Daiichi Enters Funded Research Agreement With Cyntellect

01-Apr-2005

Cyntellect, Inc., a privately-held biotechnology company, announced the company has entered into a research agreement with Daiichi Pharmaceutical Co., Ltd. ("Daiichi") to utilize Cyntellect's high-throughput cell imaging and laser-based cell manipulation technology, LEAP(TM), for novel drug discovery.

Under the terms of the collaboration, Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi. Specific financial terms were not disclosed.

"We are pleased to establish a formal research relationship with Daiichi, one of Japan's leading pharmaceutical companies," stated Dr. Fred Koller, President and CTO. "Daiichi's commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances